Institute for International Research

"TIDES has become the leading US conference on therapeutic oligos and peptides and the new format of a separate stream on Oligonucleotide Therapeutics Discovery has enhanced the value of this conference even further."
- Michael Gait, Ph.D., MRC Programme Leader, Labortory of Molecular Biology, Medical Research Council, United Kingdom

"This conference has the most comprehensive content of any "tides" specialty meeting, ranging from basic science to all aspects of product development."
- Doug Kornbrust, Ph.D., President, Preclinsight

"Definitely the best meeting in the US for companies developing new peptide therapeutics; not to be missed."
- Rodney Lax, Director, Business Development, PolyPeptide Laboratories, Inc.

"I found the conference to be very worthwhile and informative."
- Ernest V. Linek, Senior Partner, Banner & Witcoff, Ltd.

"I enjoyed TIDES which was both helpful and fun, very much.. The talks were very relevant … it was one of my best meetings ever."
- Guy A. Tremblay, M.Sc., Research Scientist, Immunochemistry, Charles River Laboratories, Canada

"This was a very useful conference that helps cross-fertilize all the industries and experts in the field."
- G. Mike Makrigiorgos, Ph.D., Associate Professor and Director, Physics and Biophysics Division, Radiation Oncology, Dana Farber Cancer Institute, Harvard Medical School

"This is an opportunity to interact with many of the key players in the field at one event."
- George A. Heavner, Ph.D., Distinguished Research Fellow, Centocor, Inc.

"Given the industry's infancy in developing oligonucleotide therapeutics, the TIDES® conference provides an extremely valuable way to stay up to date and interact with colleagues involved with this fast-moving landscape."
- Daren S. Levin, Ph.D., Investigator, Inhaled Product Development, GlaxoSmithKline

"TIDES® is the premier event for all things RNA/DNA related, to learn what is going on and to meet all the players in the field."
- David Macdonald, Director of Chemical Development, Agilent Technologies

"One of the great meetings for anyone involved or interested in any aspect of our industry."
- Louis St.L. O'Dea, MD, FRCP(C), Senior Vice President and Chief Medical Officer, Radius Health, Inc.

"TIDES® provides an outstanding opportunity to establish and intensify contacts to people in the oligonucleotide business as well as to learn about new developments and trends in the therapeutic oligonucleotide area."
- Hueseyin Ayguen, Ph.D., CSO, Nucleic Acid Technologies, BioSpring GmbH, Germany

"Will provide much-needed insights into the challenges and potential of moving these therapeutics from the bench to the clinic."
- Mark L. Peterson, Ph.D., Vice President, IP & Operations, Tranzyme Pharma Inc., Canada

"TIDES® provides an excellent forum for colleagues from different functional areas to understand the challenges related to the co-development of therapeutics and diagnostics."
- Helen Wu, Ph.D., Research Leader, Genomics and Oncology, Roche Molecular Systems, Inc.

"The TIDES® conference is the place to be to learn new technologies related to the peptide industry and to network with some of the world leaders in the field."
- Nicolas Mourier, Ph.D., Director of Product Development, Peptimmune, Inc.

"TIDES® has always been an excellent forum for education."
- Nadim Akhtar, Ph.D., Senior Scientist, Astra Zeneca, United Kingdom